(Q37730056)

22 August 2017

High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective (English)

1 reference

22 August 2017

1 reference

1 reference

Yasuo Yoshioka

1

1 reference

22 August 2017

Osamu Suzuki

2

1 reference

22 August 2017

Yuki Otani

3

1 reference

22 August 2017

Ken Yoshida

4

1 reference

22 August 2017

Takayuki Nose

5

1 reference

22 August 2017

Kazuhiko Ogawa

6

1 reference

22 August 2017

1 March 2014

1 reference

Journal of contemporary brachytherapy

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

1

1 reference

22 August 2017

91-98

1 reference

Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

HDR monotherapy for prostate cancer: a simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Is alpha/beta for prostate tumors really low?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High dose brachytherapy as monotherapy for intermediate risk prostate cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

New ambulatory implant technique of high-dose-rate interstitial brachytherapy for prostate cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Optimization of dose distribution for HDR brachytherapy of the prostate using Attraction-Repulsion Model.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4003433

Fractionation and protraction for radiotherapy of prostate carcinoma

1 September 2018

1 reference

12 December 2020

Needle displacement during HDR brachytherapy in the treatment of prostate cancer

1 reference

12 December 2020

High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial

1 reference

12 December 2020

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report

1 reference

12 December 2020

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

1 reference

12 December 2020

Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer

1 reference

12 December 2020

How low is the alpha/beta ratio for prostate cancer?

1 reference

12 December 2020

High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity

1 reference

12 December 2020

GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer

1 reference

12 December 2020

Evaluation of anatomy-based dwell position and inverse optimization in high-dose-rate brachytherapy of prostate cancer: a dosimetric comparison to a conventional cylindrical dwell position, geometric optimization, and dose-point optimization

1 reference

12 December 2020

High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer

1 reference

12 December 2020

New implant technique for separation of the seminal vesicle and rectal mucosa for high-dose-rate prostate brachytherapy

1 reference

12 December 2020

A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer

1 reference

12 December 2020

Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy

1 reference

12 December 2020

Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer

1 reference

12 December 2020

Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions

1 reference

12 December 2020

High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence

1 reference

12 December 2020

High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results

1 reference

12 December 2020

Assessment of daily needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer using daily CT examinations

1 reference

12 December 2020

High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results

1 reference

12 December 2020

Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers

1 reference

12 December 2020

Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial

1 reference

12 December 2020

Identifiers

DOI

10.5114/JCB.2014.42026

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

24790627

1 reference